The Freedom SOLO bovine pericardial stentless valve: Single-center experience, outcome and long-term durability

Stanger, Olaf; Bleuel, Irina; Gisler, Fabian; Göber, Volkhard; Reineke, Sylvia; Gahl, Brigitta; Aymard, Thierry; Englberger, Lars; Carrel, Thierry; Tevaearai, Hendrik (2015). The Freedom SOLO bovine pericardial stentless valve: Single-center experience, outcome and long-term durability. Journal of thoracic and cardiovascular surgery, 150(1), pp. 70-77. Mosby 10.1016/j.jtcvs.2015.01.060

[img]
Preview
Text
1-s2.0-S0022522315001233-main.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (2MB) | Preview

Abstract Objectives We report our institutional experience and long-term results with the Sorin Freedom SOLO bovine pericardial stentless bioprosthesis. Methods Between January 2005 and November 2009, 149 patients (mean age 73.6±8.7 years, 68 [45.6%] female) underwent isolated (n=75) or combined (n=74) aortic valve replacement (AVR) using the SOLO in our institution. Follow-up was 100% complete with an average follow-up time of 5.9±2.6 years (maximum 9.6 years) and a total of 885.3 patient years. Results Operative (30-day) mortality was 2.7% (1.3% for isolated AVR [n=1] and 4.0% for combined procedures [n=3]). All causes of death were not valve-related. Preoperative peak (mean) gradients of 74.2±23.0 mmHg (48.6 ± 16.3 mmHg) decreased to 15.6±5.4 (8.8±3.0) after AVR, and remained low for up to 9 years. The postoperative effective orifice area (EOA) was 1.6 ±0.57 cm2, 1.90±0.45 cm2, 2.12±0.48 cm2 and 2.20±0.66 cm2 for the valve sizes 21, 23, 25 and 27, respectively; with absence of severe prosthesis-patient-mismatch (PPM) and 0.7% (n=1) moderate PPM. During follow-up, Twenty-six patients experienced structural valve deterioration (SVD) and 14 patients underwent explantation. Kaplan-Meier estimates for freedom from death, explantation and SVD at 9 years averaged 0.57 [0.47‒0.66], 0.82 [0.69‒0.90] and 0.70 [0.57‒0.79], respectively. Conclusions The Freedom SOLO stentless aortic valve is safe to implant and shows excellent early and mid-term hemodynamic performance. However, SVD was observed in a substantial number of patients after only 5 ̶ 6 years and the need for explantation increased markedly, suggesting low durability.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiovascular Surgery

UniBE Contributor:

Stanger, Olaf; Gisler, Fabian; Göber, Volkhard; Reineke, Sylvia; Gahl, Brigitta; Englberger, Lars; Carrel, Thierry and Tevaearai, Hendrik

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0022-5223

Publisher:

Mosby

Language:

English

Submitter:

Sara Baumberger

Date Deposited:

17 Feb 2015 08:11

Last Modified:

10 Feb 2016 02:30

Publisher DOI:

10.1016/j.jtcvs.2015.01.060

PubMed ID:

25769775

BORIS DOI:

10.7892/boris.63202

URI:

https://boris.unibe.ch/id/eprint/63202

Actions (login required)

Edit item Edit item
Provide Feedback